RxDoctor Payments Data

Raymond Paxton, MD

Internal Medicine · West Lake Hills, TXNPI 1114981529

Payments from drug & device makers

$3,185in general payments, 2019–2025

Across 201 payments — averaging $15.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$396
  • Boehringer Ingelheim$350
  • GSK$299
  • AstraZeneca$296
  • Amgen$206
  • Radius Health, Inc.$177
  • plus $1K from 27 others

What the payments were for

  • Food & beverage$3,176100%
  • Education$80%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,185 in reported general payments places this provider in the 80th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$213,061
Medicare patients
332
Services billed
5,265

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide60$76,478
JardianceEmpagliflozin48$62,462
JanuviaSitagliptin Phosphate27$35,233
EliquisApixaban37$28,717
MounjaroTirzepatide24$27,473
VascepaIcosapent Ethyl27$25,269
MyrbetriqMirabegron20$23,368
Synjardy XrEmpagliflozin/Metformin Hcl12$18,499
Spiriva RespimatTiotropium Bromide17$14,681
Trelegy ElliptaFluticasone/Umeclidin/Vilanter11$12,035
Icosapent Ethyl23$7,768
Rosuvastatin Calcium390$5,955
Atorvastatin Calcium395$3,625
Duloxetine Hcl142$3,266
Olmesartan Medoxomil93$3,198

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Synjardy Xr, Spiriva Respimat$350$95,64377 claims
Novo NordiskOzempic$396$76,47860 claims
MerckJanuvia$146$35,23327 claims
PfizerEliquis$31$28,71737 claims
Lilly USA, LLCMounjaro$167$27,47324 claims
Astellas Pharma US IncMyrbetriq$61$23,36820 claims
GSKTrelegy Ellipta$299$12,03511 claims
AbbVieSynthroid$122$3,06649 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in West Lake Hills

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →